SEC Form 4 · accession 0001127602-18-017800
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alane P Barnes
Officer — VP, General Counsel & Corp Sec
Period of report
May 15, 2018
Accepted (ET)
May 17, 2018 · 9:25 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 15, 2018 | M | 12,500 | $1.42 | A | 98,268 | D | |
| Common StockF1 | May 15, 2018 | F | 3,004 | $5.91 | D | 95,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $1.42 | May 15, 2018 | M | 12,500 | D | Jan 1, 2014 | Jan 1, 2023 | Common Stock | 12,500 | 8,132 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.